About tenax therapeutics - TENX
Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.
TENX At a Glance
Tenax Therapeutics, Inc.
101 Glen Lennox Drive
Chapel Hill, North Carolina 27517
| Phone | 1-919-855-2100 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -17,602,000.00 | |
| Sector | Health Technology | Employees | 6 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
TENX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.23 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.016 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
TENX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,933,666.667 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
TENX Liquidity
| Current Ratio | 20.602 |
| Quick Ratio | 20.602 |
| Cash Ratio | 20.211 |
TENX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -32.485 |
| Return on Equity | -35.172 |
| Return on Total Capital | -19.134 |
| Return on Invested Capital | -35.172 |
TENX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |